Sale of the company to Takara Bio Inc.
Sale of the company to Thermo Fisher Scientific Inc.
Strategic acquisition of TriLink Biotechnologies.
Strategic acquisition of Cygnus.
Sale of the company to PerkinElmer, Inc.
Clarity Medical Systems has sold its RetCam Ophthalmic
Imaging System business to Natus Medical.
Sale of the company to Laboratory Corporation of America.
Strategic equity investment in Vector Laboratories, Inc.
Sale of the company to OpGen, Inc.
Sale of the iPS Cell Business Unit of Stemgent
to ReproCELL, Inc.
Sale of miRInform Thyroid™ and Pancreas Test
to PDI Inc.
Sale of company to StoneCalibre.
Equity investment and strategic collaboration with
Brooks Automation, Inc.
Sale of in-vivo preclinical services business to
Sale of sequencing services business to
BioReference Laboratories, Inc.
Sale of the Life Science business of SDIX to
OriGene Technologies, Inc.
Sale of UVP LLC to Analytik Jena AG.
Sale of BioServices business to
Sale of Food Safety and GMO businesses
to Romer Labs.
Sale of preclinical in-vivo imaging business to Bruker.
Exclusive placement agent for OpGen, Inc.
BroadOak Partners provided financial advisory
services to Quanta Biosciences.
Non-exclusive license agreement with QIAGEN.
BroadOak retained to provide ongoing financial
SVT gains exclusive rights in China to ENMD-2076 through
an investment in EntreMed, Inc.
Replacement and expansion of Cayman Chemical
Company’s debt facilities.
Acquisition of Hyaluron, Inc.
Acquisition of GlobalStem, Inc.
Sale of in-vivo preclinical CRO services business to
Taconic Farms, Inc.
Sale of Alpha Innotech Corp. to Cell Biosciences, Inc.
Collaboration and license agreement with Novartis.
Sale of non-core assets to Intrexon Corporation.
Sale of Assay Designs, Inc. to Enzo Biochem, Inc.
Sale of Semrock Inc. to IDEX Corp.
Acquisition of biodefense vaccines business from
Avecia Biologics Limited.
Sale of Fluorescent Detection Products Business.